



Differentiate your incretin-based therapies and SGLT2 inhibitors in DIO mice: clues for positioning


Differentiate your drug against competitors beyond anti-diabetic effects with validated *in vivo* experiments

Key objectives:

- In vivo validation of the main classes of approved anti-diabetic compounds
- Differentiate your drug against competitors through in vivo experiments to unmask specific benefits/scientific advantages
- ✓ Take advantage of Physiogenex's unique state of the art technical and scientific expertise


ANIMAL MODEL

- · C57BL6/J,, 8-week old male mice
- 60% high fat diet over 12 weeks to induce obesity, glucose intolerance and insulin resistance
- Positive reference compounds: GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors



Body weight follow-up (A, B) and body weight loss (C, D) in vehicle, exendin-4, liraglutide, sitagliptin and dapagliflozin-treated mice

Exendin-4 and liraglutide induce substantial body weight loss




Blood glucose (A, C) and plasma insulin (B, D) levels after an oral glucose load in vehicle, exendin-4, liraglutide, sitagliptin and dapagliflozin treated mice

Exendin-4 and sitaglitptin increase glucose-induced insulin secretion

*p<0.05, **p<0.01, ***p<0.001 vs.vehicle


DIFFERENTIATION ON INTESTINAL LIPIDS ABSORPTION



In vivo intestinal cholesterol (A, B) and triglycerides (C, D) absorption in mice treated with vehicle, exendin-4, liraglutide, sitagliptin and dapagliflozin

Exendin-4, liraglutide and dapagliflozin reduce intestinal cholesterol absorption

DIFFERENTIATION ON GLUCOSE/LIPID PROFILE DURING A MEAL TEST



Postprandial blood glucose (A, B), free fatty acids (C, D) and triglycerides levels during a test meal in mice treated with vehicle, exendin-4, liraglutide, sitagliptin and dapagliflozin

Exendin-4, liraglutide and dapagliflozin all reduce blood glucose levels but differentially alter plasma lipids levels



metabolic

Prologue Biotech – 516, rue Pierre et Marie Curie 31670 Labège - FRANCE Phone : +33 561 287 040 Fax : +33 561 287 043 www.physiogenex.com business@physiogenex.com